Canine CD20 gene.

Area of Science:

• Veterinary Medicine
• Immunology
• Molecular Biology

Background:

• The CD20 antigen is a key target for B-cell lymphoma therapy in humans.
• Understanding canine CD20 is crucial for developing similar targeted therapies in veterinary oncology.

Purpose of the Study:

• To clone and sequence the canine CD20 gene.
• To investigate the expression of canine CD20 mRNA in various canine tissues and cell types.
• To evaluate the potential of canine CD20 as a therapeutic target for canine B-cell lymphoma.

Main Methods:

• Cloning and sequencing of the full-length canine CD20 gene using 5'-RACE and 3'-RACE.
• Bioinformatic analysis of the canine CD20 amino acid sequence for domain prediction.
• Reverse transcription polymerase chain reaction (RT-PCR) to detect CD20 mRNA expression in peripheral blood mononuclear cells (PBMCs), lymph nodes, and lymphoma cells.

Main Results:

• The full-length canine CD20 cDNA sequence is 1239bp, encoding 297 amino acids.
• Canine CD20 shares significant sequence similarity with human and mouse CD20, with predicted similar domain structures.
• Canine CD20 mRNA was detected in PBMCs and lymph nodes of healthy dogs and in B-cell lymphoma samples, but not in T-cell or non-B/non-T lymphoma cells.

Conclusions:

• The canine CD20 gene has been successfully cloned and characterized.
• Canine CD20 is specifically expressed on B-cells, making it a potential biomarker for B-cell lymphomas.
• Canine CD20 represents a promising target for developing novel monoclonal antibody-based therapies for canine B-cell lymphoma.